The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure

• Status: Terminated
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Carperitide (alpha-human atrial natriuretic peptide) improves systemic hemodynamics in patients with heart failure through a vasodilatory action, a natriuretic action, and inhibition of the renin-angiotensin-aldosterone system and has been widely-used in Japan. However, a paucity of report is available on the effects of carperitide on short and long-term prognosis in patients with both cardiac and renal failure. The purpose of this study is to evaluate the effects of carperitide therapy on short and long-term prognosis in patients with both cardiac and renal failure, in comparison with standard therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nara Medical University
• Treatments: Diuretics; Sodium Potassium Chloride Symporter Inhibitors

Criteria

Inclusion Criteria:

• Heart failure of any etiology, diagnosed according to Framingham criteria

• Estimated GFR Exclusion Criteria:

• Severe heart failure required percutaneous cardiopulmonary bypass support (PCPS)

• End-stage renal failure on maintenance dialysis

• Severe hepatic dysfunction

• Severe anemia

• Allergic history of carperitide

• Pregnant women